{"disease":{"id":"mixed-lineage-acute-leukemia","name":"mixed lineage acute leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04065399","title":"A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":447,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT04067336","title":"First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":263,"lead_sponsor_name":"Kura Oncology, Inc.","has_results":false},{"nct_id":"NCT04375631","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT05761171","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":78,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02419755","title":"Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}